Nuwellis, Inc. announced a leadership transition where John L. Erb resigned as CEO and will remain as Chairman of the Board. Michael McCormick, a medical device executive with extensive experience, was appointed as the new CEO and President and a member of the Board, effective June 30, 2026. McCormick's employment agreement includes a $431,100 annual base salary and a target 65% annual incentive compensation. The Board of Directors has also been expanded from five to six members. Nuwellis, Inc. is a medical device company focused on kidney-related technologies.
